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Background: The endothelial glycocalyx layer (EGL) is a key regulator of vascular permeability, cell adhesion, and
inflammation. The EGL is primarily composed of syndecan-1, hyaluronic acid (HA), heparan sulfate (HS) and chondroitin
sulfate (CS). While many studies have observed increased shedding of syndecan-1 during hemorrhagic shock, little is
known about the shedding of other EGL components, and their effects on altered permeability and coagulation. We
characterized shedding of all four primary components of the EGL, as well as the plasma’s effect on permeability and
thrombin generation in a cohort of trauma patients.
Methods: Plasma samples were collected from 5 healthy consented volunteers and 22 severely injured trauma patients
upon admission to the emergency department. ELISA assays were performed to quantify shed HA, HS, CS and
syndecan-1 in plasma. A colloid osmometer and Electric Cell-substrate Impedance Sensing (ECIS) system were
used to measure plasma colloid osmotic pressure (COP) and cell permeability, respectively. Thrombin generation
was measured using a calibrated automated thrombogram (CAT). Initial vital signs, routine laboratory values, and injury
severity scores (ISS) were recorded. Non-parametric statistical tests were used to compare differences between groups.
Results: We observed increased shedding of all four proteins in trauma patient plasma compared to healthy controls:
31.7 vs. 21.2 U/L of CS, 175.8 vs. 121.9 ng/ml of HS, 946.7 vs. 618.6 ng/ml of HA and 245.8 vs. 31.6 ng/ml of syndecan-1
(all p < 0.05). Patients with low plasma COP (≤16 mmHg) had significantly increased syndecan-1 and HA compared to
those with normal COP, which corresponded to increased cell permeability via ECIS. CS and HS did not vary between
COP groups. Lastly, patients with low COP displayed reduced peak thrombin generation of less than 250 nM on
average (p < 0.05).
Conclusions: Glycocalyx components were shed more in trauma patients compared to healthy controls in this
cohort. However, only syndecan-1 and HA shedding were significantly higher in patients with reduced plasma
COP. Thrombin generation was impaired in patients with low plasma COP. These data suggest that low plasma
COP correlates well to glycocalyx degradation and thrombin loss following trauma, which consequently affect
permeability and coagulation.
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Hemorrhagic shock is the leading cause of mortality in
both civilian and military populations. Nearly 50% of
hemorrhagic deaths occur within 3–6 hours of injury
[1]. Many of these deaths are considered potentially pre-
ventable with appropriate care and resuscitation. Recent
efforts in resuscitation for massively injured patients
have focused on not only restoring the blood volume
lost, but also ameliorating the inflammatory and coagu-
lopathic responses, vascular permeability and endothelial
dysfunction [2-4]. As a result, a number of biomarkers
for coagulation and endothelial integrity have emerged.
Endothelial dysfunction and vascular permeability (i.e.
“capillary leak”) have been associated with increased
morbidity and mortality; in particular, sepsis, multi-
organ failure and hemorrhagic shock [5,6].
The vascular endothelium is protected by a thin layer
of cell-bound proteoglycans and glycoproteins, com-
monly referred to as the endothelial glycocalyx layer
(EGL) [7-12]. The major components of the EGL are
syndecans, hyaluronic acid (HA), chondroitin sulfate
(CS) and heparan sulfate (HS) [7-12]. The EGL plays a
critical role in maintaining vascular integrity by serving as
a (1) barrier to the transport of proteins and fluids, there-
fore preventing “capillary leak”, (2) mechano-transducer of
pressure and shear stress, and (3) regulator of inflamma-
tory cell adhesion and infiltration [7-12]. Furthermore, the
EGL has been shown to serve as a significant binding site
for antithrombin III (ATIII), tissue factor pathway inhibi-
tor, vascular endothelial growth factor (VEGF), fibroblast
growth factor (FGF), and lipoprotein lipase [10-12].
Once the EGL is disrupted, endothelial cells are ex-
posed consequently allowing for the adhesion of plate-
lets, leukocytes and other neutrophil-endothelial cell
interactions [8,12,13]. Several studies have shown in-
creased shedding of syndecan-1, catecholamines and cy-
tokines following hemorrhagic shock in both in vitro
and rodent models [3,14-21]. Shedding of syndecan-1
has been shown to be ameliorated with freshly frozen
plasma (FFP) resuscitation, suggesting that FFP may play
a role in the partial restoration of the EGL [3,15,18].
More recently, Torres et al. have shown restoration of
syndecan-1 and heparan sulfate levels with FFP and
fresh whole blood resuscitation in an animal model of
hemorrhagic shock, which also correlated to EGL repair
[19-21]. Resuscitation with FFP has also been associated
with modulation of syndecan-1 shedding in human sub-
jects [5]. Trauma patients who had high levels of shed
syndecan-1 also demonstrated higher levels of IL-10, an
inflammatory cytokine [5]. Chappell et al. observed
significant shedding of the EGL with ischemic injury and
preservation of the EGL with ATIII treatment [14].
Thus, the EGL may play a critical role in the inflamma-
tory and coagulopathic responses post-injury.In the case of hemorrhagic shock and injury, there is
also a substantial hemodynamic response. As the patient
becomes hypotensive, there is a reduction in hydrostatic
and plasma colloid osmotic pressures (COP, also referred
to as oncotic pressure), which affects the flux of fluid
and solutes between the vascular and interstitial com-
partments as dictated by the revised Starling principle
[22,23]. Plasma COP is the pressure exerted by large
molecules on the semi-permeable membranes between
the capillary and interstitial spaces. We have previously
shown that reduced plasma COP is associated with in-
jury severity and increased shedding of syndecan-1,
which consequently translated into increased need of
transfusions and resuscitation [24]. In this study we
conducted a secondary analysis of prospectively col-
lected data where we hypothesized that low plasma COP
would further correlate to the shedding of the four
major EGL components: HA, HS, CS and syndecan-1,
and subsequently result in increased cell permeability




This prospective observational study was conducted
under an approved IRB (Universal Study, HSC-GEN-
12-0059), which included all adult trauma patients
(≥16 years) at the highest level of activation at Memorial
Hermann Hospital Texas Medical Center (MHH-TMC).
Pregnant women and prisoners were excluded from the
study. IRB approval was obtained for delayed consent
given the nature of trauma patients, therefore consent
was obtained from the patient or their legally authorized
representative within 48–72 hours of admission, or as
soon as possible. If patients were discharged within
24 hours of admission, a waiver of consent was ob-
tained. Blood was collected from each patient in citrated
tubes on admission. Samples from patients who refused
consent were destroyed. Blood was also collected from
healthy volunteers to serve as a control group.
Osmolality, oncotic pressure and serum protein
Blood samples were centrifuged and plasma was stored
for future use at −80°C. Osmolality and COP (i.e. onco-
tic pressure) were measured from fresh plasma at room
temperature as previously described by Rahbar et al.
[24]. Briefly, plasma samples were run in duplicate with
the Wescor Vapro Osmometer (model 5520, Logan, UT)
and Wescor Colloid Osmometer (model 4420, Logan,
UT), respectively to obtain osmolality and oncotic pres-
sure readings. Based on our previous study, plasma COP
< 16 mmHg was used as the cut-off for the “low COP”
group [24]. This cut-off was determined by calculating
two standard deviations away from the average normal
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measured from fresh plasma at room temperature using
a clinical refractometer (RHC-200/ATC, C&A Scientific,
Manassas, VA).
Thrombin generation assay
Thrombin generation was measured using calibrated
automated thrombogram (CAT; Thrombinoscope, Maas-
tricht, Netherlands) in platelet-poor plasma (PPP), as
previously described by Cardenas et al. [25]. All samples
were run in duplicate in a 96-well plate and calibrated
using 20 μL of α2-macroglobulin/thrombin complex.
Each thrombogram curve results in the following
parameters: lag time (time to initiation of thrombin
formation; min), endogenous thrombin potential (ETP;
the area under the curve; nM*min), peak (maximum
thrombin concentration; nM), and “time to peak”
(ttPeak; min).
Enzyme-linked immunosorbant assays
Commercial enzyme-linked immunosorbant assays (ELI-
SAs) for soluble syndecan-1, chondroitin sulfate, heparan
sulfate and hyaluronic acid were performed to quantify
levels of endothelial glycocalyx component degradations
(Syndecan-1: Abcam, Cat. No. ab46506, Cambridge, MA;
Heparan Sulfate: Biotang, Cat. No. HU8718, Lexington,
MA; Chondroitin Sulfate: Biotang, Cat. No. HU8720,
Lexington, MA; Hyaluronic Acid: R&D Systems, Cat. No.
DHYAL0, Minneapolis, MN). Adrenaline and noradren-
aline were measured in uniplicate in plasma by com-
mercially available ELISA kits (2-CAT ELISA; Labor
Diagnostica Nord GmbH & Co KG, Nordhorn, Germany;
lower limit of detection [LLD]) 10 pg/mL (adrenaline;
normal reference, < 100 pg/mL) and 50 pg/mL (nor-
adrenaline; normal reference, < 600 pg/mL), respect-
ively [16]. Frozen citrated plasma samples were used for
all ELISA assays, except for measuring HA and cate-
cholamines, which used frozen plasma stored in Ethyl-
enediaminetetraacetic acid (EDTA). All other samples
were run in duplicate. Samples that were over the detec-
tion range of the assay were diluted and rerun as
needed.
Endothelial cell permeability
Cell barrier function was assessed by measuring trans-
endothelial electrical resistance (TEER) in real time using
the Electric Cell-substrate Impedance Sensing (ECIS®
1600, Applied BioPhysics, Troy, NY) system as described
by Giaever and Keese [26,27]. Briefly, human umbilical
vein endothelial cells (HUVECs) were grown to conflu-
ence on L-cysteine reduced, Fibronectin-coated 96W10E
electrodes (Applied BioPhysics, Troy, NY) in endothelial
growth medium (EGM-2; Lonza Inc., Walkersville, MD),
and serum starved for one hour in endothelial basalmedium (EBM-2; Lonza Inc., Walkersville, MD) before
treatment. Cells were treated with 10% of the frozen
plasma in 200 μL of EBM-2 medium. Monolayer resist-
ance was recorded at 4 kHz over eight-minute intervals
for 24 hours. A change in TEER across the cell monolayer
indicated increased or decreased paracellular permeability.
Analysis of ECIS data
For analysis of changes in barrier function, TEER mea-
surements at 4 kHz were averaged over the first five
available post-treatment time points. Mean TEER values
were then computed for each plasma sample (trauma
patients and healthy volunteers). Normalized TEER values
were also calculated by dividing each well by its baseline
value (prior to plasma sample addition).
Clinical parameters
Clinical laboratory results from the time of admission
were collected into a database for the consented pa-
tients. This included: admission vital signs, complete
blood count test results, pH, base excess, clinical coagu-
lation tests including prothrombin time (PT), activated
partial thromboplastin time (aPTT), international nor-
malized ratio (INR), pre-hospital fluids, 24 hour blood
transfusions (including packed red blood cells (RBCs),
freshly frozen plasma (or thawed plasma) and apheresis
platelets), 24 hour crystalloid infusions, complications,
injury severity score (ISS) and patient outcomes. Total
blood units at 24 hours were calculated as the cumula-
tive number of units of blood products transfused within
the first 24 hours, using the same conversions as previ-
ously published by Rahbar et al. [28]. Patient demo-
graphics such as age, gender, race, and mechanism of
injury were documented.
Statistical analysis
All statistical analyses were conducted with commer-
cially available software, STATA (12.1, College Station,
TX). Non-parametric tests, including Kruskal-Wallis and
Chi-square tests, were used to assess differences between
Low and Normal COP groups. Median and inter-quartile
(IQR) values are reported throughout. Multiple compari-
sons were made to determine differences between healthy
controls and the Low vs. Normal COP groups. No correc-
tions for multiple comparisons were performed. Statistical
significance was set at the 5% level. A multivariable linear
regression for permeability was developed while adjusting
for age, gender, base excess, injury severity and pre-
hospital fluids. A negative binomial regression was devel-
oped to assess the incidence risk ratio (IRR) of low plasma
COP and the shedding of glycocalyx components on blood
transfusion requirements, while adjusting for the afo-
rementioned variables used in the multivariable linear
regression.
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A total of 22 trauma patient plasma samples and 5 healthy
volunteer plasma samples were used to characterize the
glycocalyx component shedding and their effect on endo-
thelial cell permeability. The overall patient demographics
were 73% male, median age of 44 years, median ISS of 22,
base excess of −2 (−3,0) and an overall in-hospital mortal-
ity rate of 36% (Table 1). Patients in the low COP group
were more severely injured as demonstrated by the higher
ISS, had worse pH and base excess levels and received
more blood transfusions within 24 hours compared to the
normal COP group (Table 1). These patient demographics
and characteristics are consistent with our previously pub-
lished work [24].
Glycocalyx shedding, catecholamines and endothelial
permeability
We observed significant increases in shedding of
syndecan-1 and HA in trauma patients with low plasma
COP compared to those with normal COP (Table 2).
Median syndecan-1 levels were 6 times higher in pa-
tients with low COP compared to those with normal
COP (222 ng/ml vs. 35 ng/ml, Table 2). Shed CS and HS
chains were significantly higher in trauma patients com-
pared to the healthy controls, but no detectable differ-
ence between the low and normal COP groups was
observed. With regards to catecholamines, we observed
almost a 10-fold increase in adrenaline levels in the low
COP group compared to the normal COP group (p =
0.014), but no statistically significant increase in nor-
adrenaline levels (p = 0.25) (Table 2). These increases in
glycocalyx shedding and catecholamines correspondedTable 1 Patient demographics, admission vitals, resuscitation
Overall (N = 22) No
Age (yrs) 44 (31, 54) 46
Male, n (%) 16 (73%) 8 (7
Penetrating, n (%) 5 (23%) 1 (9
SBP (mmHg) 122 (108, 140) 136
DBP (mmHg) 67 (54, 80) 75
HR (bpm) 99 (79, 116) 98
RR (bpm) 17 (15, 20) 16
GCS 9 (3, 15) 8 (3
ISS 22 (13, 34) 19
pH 7.27 (708, 7.35) 7.3
Base excess (mEq/L) −2 (−3, 0) −1
24 hr-total blood (U) 5 (0, 28) 2 (0
24 hr-total crystalloid (mL) 2200 (1287, 4800) 171
Length of stay (days) 7 (2, 20) 5 (2
Mortality, n (%) 8 (36%) 3 (2
Median and inter-quartile range (IQR) values with the 25th and 75th percentiles in p
Low and Normal COP groups (p < 0.05).to reduced TEER (i.e. increased permeability) as mea-
sured by ECIS, which reflect endothelial barrier integrity
in vitro. HUVECs treated with 10% of plasma from the
two groups reflected lower median endothelial resis-
tances in the low COP group vs. the normal COP group
(1067 Ωcm2 vs. 1101 Ωcm2, Table 2).Thrombin generation
Patients with low plasma COP had shorter lag times, less
ETP, reduced peak and similar ttPeak values compared to
patients with normal COP. However, only peak thrombin
generation was statistically significant (Table 3). A repre-
sentative thrombogram from the CAT assay is illustrated
in Figure 1. No remarkable differences in INR, aPTT or
PT values were observed between groups. Platelet count
was not statistically different between groups.Correlations to patient outcomes and clinical parameters
Shed CS and HS were highly correlated (r = 0.95, p <
0.001) to each other, and HS was strongly associated with
ISS (r = 0.60, p = 0.053). However, CS was not strongly
associated with ISS (r = −0.21, p > 0.05). Hyaluronic acid
exhibited the strongest correlation to ISS (r = 0.65, p =
0.03). ISS is a measure of anatomical injury, and so this
correlation suggests that HA shedding is correlated to
anatomical injury or more specifically increased tissue
damage. Further, plasma COP was significantly associated
with peak thrombin generation (r = 0.61, p = 0.03). More
specifically, circulating syndecan-1 levels were inversely
associated with ETP (r = −0.44, p = 0.048) and peak
thrombin generation (r = −0.49, p = 0.02).volumes and outcomes
rmal COP (N = 11) Low COP (N = 11) p-value
(31, 56) 41 (29, 51) 0.74
3%) 8 (73%) 0.69
%) 4 (36%) 0.22
(119, 151) 119 (93, 123) 0.09
(59, 80) 60 (51, 74) 0.17
(90, 116) 99 (78, 126) 0.95
(0, 18) 18 (15, 22) 0.28
, 15) 10 (3, 14) 0.73
(9, 22) 34 (17, 43)* 0.02
5 (7.23, 7.42) 7.19 (6.91, 7.31)* 0.03
(−3, 0) −3 (−10, 0) 0.23
, 6) 28 (3, 41)* 0.006
0 (1049, 7100) 2875 (1287, 4800) 0.82
, 17) 9 (2, 24) 0.87
7%) 5 (45%) 0.37
arentheses are reported. Asterisks (*) indicate statistical difference between
Table 2 Summary of measured glycocalyx components, catecholamines and ECIS resistance
Healthy controls (N = 5) Normal COP (N = 11) Low COP (N = 11) p-value
Plasma COP (mmHg) 21.2 (19.1, 21.3) 21.6 (16.2, 21.9) 12.4 (10.7, 13.9)a,b <0.001
Chondroitin sulfate (U/L) 22.9 (22.5, 23.3) 32.3 (31.3, 33.7)a 32.7 (27.6, 33.9)a 0.003
Heparan sulfate (ng/ml) 133.9 (130.5, 138.3) 180.0 (176.4, 185.9)a 176.7 (151.5, 185.8)a 0.003
Hyaluronic acid (ng/ml) 627.6 (484.1, 753.1) 93.5 (49.0, 885.4) 380.9 (216.6, 682.4)a,b 0.035
Syndecan-1 (ng/ml) 31.6 ± 15.3* 34.6 (19.3, 43.1) 221.7 (88.3, 477.4)a,b <0.001
Adrenaline (ng/ml) 72.1 ± 99.2† 90.5 (58.7, 226.9) 805.8 (659.3, 4319.3)a,b 0.014
Noradrenaline (ng/ml) 282 ± 454.7† 739.8 (189.5, 1006.2) 987.1 (352.3, 1187.4) 0.245
TEER (Ωcm2) 1066.3 (1057.8, 1074.8) 1101.6 (1089.6, 1115.5) 1067.3b (1043.7, 1096.4) 0.016
Normalized TEER 1.30 (1.29, 1.31) 1.35 (1.33, 1.38) 1.31 (1.27, 1.33) 0.016
Median and IQR values are reported for each group. Kruskal-Wallis test was used to assess differences between groups (p-values shown). Multiple comparisons
were also made: first comparing trauma patients to healthy controls and then comparing Low COP to Normal COP; aindicates significant difference from healthy
controls, bindicates significant difference between Low and Normal COP groups (p < 0.05).
*Reference value for syndecan-1 levels in healthy volunteers was provided by Abcam.
†Adrenaline and noradrenaline healthy control values were obtained from Ostrowski et al. 2013 [16].
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ity, as measured by ECIS, was developed. We observed that
plasma from patients with low COP exhibited decreased
resistance (i.e. more permeable), of 63 Ωcm2 on average
(95% CI [47.8, 79.5 Ωcm2]), compared to plasma from
patients with normal COP, while adjusting for age, gen-
der, admission laboratory values, ISS and pre-hospital
fluids. Furthermore, we determined that for every unit
decrease in plasma COP, there is a 6.5 Ωcm2 drop in
resistance, on average (95% CI [3.1, 10.05]). Plasma
COP demonstrated the strongest association with TEER
measurements, more than any of the individual EGL
components (r = 0.64, p = 0.006).
A negative binomial regression for the total number
of blood products transfused within the first 24 hours
was developed. We observed that plasma COP, shed
syndecan-1 and HA were significantly associated with
increased number of blood transfusions within the first
24 hours. The incidence risk ratio for the low plasma
COP group was 4.97 with 95% CI [1.12, 22.07], p = 0.035,
while adjusting for age, gender, base excess, ISS and
pre-hospital fluids. This means that patients who had
low plasma COP were nearly 5 times more likely toTable 3 Summary of CAT parameters and conventional
clinical coagulation tests
Normal COP (N = 11) Low COP (N = 11) p-value
Lag time (min) 3.83 (3.46, 4.83) 3.78 (3.33, 4.83) 0.77
ETP (nM*min) 1227 (1011, 1314) 1053 (1009, 1223) 0.53
Peak (nM) 325.4 (277.7, 352.2) 249.4 (177.4, 285.8)* 0.02
ttpeak (min) 5.7 (5.3, 6.7) 5.7 (5.3, 6.7) 0.97
INR 1.12 (1.07, 1.22) 1.19 (1.09, 1.59) 0.28
aPTT (s) 28.3 (26.5, 33.4) 32.8 (24.6, 43.1) 0.67
PT (s) 14.4 (13.9, 15.4) 15.1 (14.1, 18.9) 0.28
Median and IQR values are reported for each group. Peak thrombin generation
is significantly lower in the Low COP group, as denoted by the asterisk (*).receive blood transfusions than those with normal COP.
As expected, patients who received pre-hospital fluids
were more injured and thus required more blood trans-
fusions (IRR: 3.1 with 95% CI [1.7, 5.6], p < 0.001).Discussion
Trauma patients with low plasma COP (< 16 mmHg)
demonstrated increased shedding of EGL components,
increased induced endothelial cell permeability in vitro,
increased sympathoadrenal activation and hence circu-
lating catecholamines, and reduced thrombin generation
potential. The results from this small prospective study
suggest that changes in the fluid mechanics, EGL and
coagulopathy are associated with one another in severely
injured trauma patients.Figure 1 Representative thrombograms for trauma patients with
Low (gray circle) vs. Normal (black square) plasma colloid osmotic
pressure. Patients with low plasma COP have a marked reduction
in peak thrombin generation (p < 0.05) compared to those with
normal COP.
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syndecan-1 shedding in severely injured trauma patients
[5,17]. Syndecan-1 levels were associated not only with
low plasma COP but also injury severity (i.e. ISS). Inter-
estingly, HA was significantly higher in patients with
low plasma COP, but there were no detectable differ-
ences in CS and HS levels between the low and normal
COP groups. Together, the loss of syndecan-1 and HA
along with the subsequent catecholamine response co-
incided with increased induced endothelial cell perme-
ability in vitro. This data suggests that HA and its
receptor (i.e. the CD44 receptor) may play a role in the
maintenance of the EGL and vascular integrity during
hemorrhagic shock. Rubio-Gayosso et al. have shown
that effects of ischemia-reperfusion injury were partially
prevented or reversed with intravascular infusion of
exogenous HA [29]. Zeng et al. have reported the role
of CS and HA in albumin binding and vascular perme-
ability but the primary mechanisms of its release and
capture remain unknown [30]. This study warrants
further investigation of the role of HA and the CD44
receptor in maintaining vascular integrity during injury/
hemorrhage and resuscitation.
Patients with low plasma COP had median peak
thrombin concentrations less than 250 nM, while show-
ing no other significant coagulopathy. Nevertheless, this
cut-off for thrombin generation <250nM has been asso-
ciated with worse outcomes and increased need for
blood transfusions in a larger cohort of severely injured
trauma patients [25]. A possible explanation for the re-
duced thrombin generation in the low COP group is that
they are more injured and thus the thrombin is being
consumed to achieve primary hemostasis. Patients with
a combination of thrombin deficiency and increased
EGL shedding could potentially be at the highest risk
for morbidities such as acute lung injury, sepsis or
multi-organ failure. These data suggest that developing
resuscitation techniques that restore plasma proteins
for improved plasma oncotic pressures, thrombin gen-
eration and ultimately the EGL could possibly improve
outcomes for these severely injured patients.
The main limitation of this study is the relatively small
sample size. We were able to conduct the ECIS mea-
surements and additional glycocalyx component analysis
on a small subset of our previously published cohort due
to limited plasma sample volumes. Though smaller than
the original cohort, the overall patient demographics of
this subset group were consistent with the complete
group, previously described by Rahbar et al. [24]. We
also ensured to achieve a minimum of 75% power at the
0.05 significance level with this secondary subset ana-
lysis. Another limitation is that we measured circulating
levels of the glycocalyx components from human plasma
samples. While we know that the major source of theseproteins is the endothelium, some of these glycocalyx
components are also present on epithelial cells and some
HA can be found on macrophages. Therefore it is diffi-
cult to ascertain the origin of the glycocalyx components
in these human samples. In general, however, these
components are considered to be glycocalyx injury bio-
markers that are recognized by the research community.
Future prospective studies are needed to evaluate new
resuscitation techniques that can preserve the EGL
during hemorrhage and resuscitation.
Conclusions
The findings from this study reveal some of the interac-
tions between the mechanical stimuli (i.e. plasma COP,
hydrostatic pressures), endothelial barrier function, and
coagulopathy in trauma patients. Plasma COP tends to
correlate well not only with glycocalyx degradation, but
also low thrombin generation potential. These interac-
tions need to be studied in greater detail to reveal the
key mechanisms of hemorrhagic shock and resuscitation,
which will ultimately help patient care by developing
improved targeted resuscitation strategies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ER collected samples, conducted ELISA assays and the statistical analysis. JCC
performed CAT assays. GB, BU, SP assisted in the ECIS measurements and
analysis. SRO and PIJ conducted the catecholamine assays. All authors were
involved with writing and editing of the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
Funding for this study was provided by the University of Texas Health
Science Center, start-up funds for CEW.
Author details
1Department of Surgery, Center for Translational Injury Research, University
of Texas Health Science Center, Houston, TX, USA. 2Department of
Biomedical Engineering, Wake Forest University, 575 N. Patterson Ave, Suite
120, Winston-Salem, NC 27101, USA. 3Blood Systems Research Institute, San
Francisco, CA, USA. 4Department of Laboratory Medicine, University of
California San Francisco, San Francisco, CA, USA. 5Capital Region Blood Bank,
Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Received: 23 October 2014 Accepted: 1 April 2015
References
1. Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, et al.
The prospective, observational, multicenter, major trauma transfusion
(PROMMTT) study: comparative effectiveness of a time-varying treatment
with competing risks. JAMA Surg. 2013;148(2):127–36.
2. Pierce A, Pittet JF. Inflammatory response to trauma: implications for
coagulation and resuscitation. Curr Opin Anaesthesiol. 2014;27(2):246–52.
3. Peng Z, Pati S, Potter D, Brown R, Holcomb JB, Grill R, et al. Fresh frozen
plasma lessens pulmonary endothelial inflammation and hyperpermeability
after hemorrhagic shock and is associated with loss of syndecan 1. Shock.
2013;40(3):195–202.
4. Midwinter MJ, Woolley T. Resuscitation and coagulation in the severely
injured trauma patient. Philos Trans R Soc Lond B Biol Sci.
2011;366(1562):192–203.
Rahbar et al. Journal of Translational Medicine  (2015) 13:117 Page 7 of 75. Haywood-Watson RJ, Holcomb JB, Gonzalez EA, Peng Z, Pati S, Park PW,
et al. Modulation of syndecan-1 shedding after hemorrhagic shock and
resuscitation. PLoS One. 2011;6(8):e23530.
6. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med.
2010;363(7):689–91.
7. Pries AR, Secomb TW, Jacobs H, Sperandio M, Osterloh K, Gaehtgens P.
Microvascular blood flow resistance: role of endothelial surface layer. Am J
Physiol. 1997;273(5 Pt 2):H2272–9.
8. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers
Arch. 2000;440(5):653–66.
9. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the
endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007;9:121–67.
10. Fu BM, Tarbell JM. Mechano-sensing and transduction by endothelial
surface glycocalyx: composition, structure, and function. Wiley Interdiscip
Rev Syst Biol Med. 2013;5(3):381–90.
11. Tarbell JM, Ebong EE. The endothelial glycocalyx: a mechano-sensor and
-transducer. Sci Signal. 2008;1(40):p. pt8.
12. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The
endothelial glycocalyx: composition, functions, and visualization. Pflugers
Arch. 2007;454(3):345–59.
13. Lipowsky HH. The endothelial glycocalyx as a barrier to leukocyte adhesion
and its mediation by extracellular proteases. Ann Biomed Eng.
2012;40(4):840–8.
14. Chappell D, Jacob M, Hofmann-Kiefer K, Rehm M, Welsch U, Conzen P, et al.
Antithrombin reduces shedding of the endothelial glycocalyx following
ischaemia/reperfusion. Cardiovasc Res. 2009;83(2):388–96.
15. Kozar RA, Peng Z, Zhang R, Holcomb JB, Pati S, Park P, et al. Plasma
restoration of endothelial glycocalyx in a rodent model of hemorrhagic
shock. Anesth Analg. 2011;112(6):1289–95.
16. Ostrowski SR, Berg RM, Windelov NA, Meyer MA, Plovsing RR, Moller K, et al.
Coagulopathy, catecholamines, and biomarkers of endothelial damage in
experimental human endotoxemia and in patients with severe sepsis:
a prospective study. J Crit Care. 2013;28(5):586–96.
17. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission
syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated
with inflammation, protein C depletion, fibrinolysis, and increased mortality in
trauma patients. Ann Surg. 2011;254(2):194–200.
18. Pati S, Matijevic N, Doursout MF, Ko T, Cao Y, Deng X, et al. Protective effects of
fresh frozen plasma on vascular endothelial permeability, coagulation, and
resuscitation after hemorrhagic shock are time dependent and diminish
between days 0 and 5 after thaw. J Trauma. 2010;69 Suppl 1:S55–63.
19. Torres Filho I, Torres LN, Sondeen JL, Polykratis IA, Dubick MA. In vivo
evaluation of venular glycocalyx during hemorrhagic shock in rats using
intravital microscopy. Microvasc Res. 2013;85:128–33.
20. Torres LN, Sondeen JL, Ji L, Dubick MA, Torres FI. Evaluation of resuscitation
fluids on endothelial glycocalyx, venular blood flow, and coagulation
function after hemorrhagic shock in rats. J Trauma Acute Care Surg.
2013;75(5):759–66.
21. Torres LN, Sondeen JL, Dubick MA, Filho IT. Systemic and microvascular
effects of resuscitation with blood products after severe hemorrhage in rats.
J Trauma Acute Care Surg. 2014;77:5.
22. Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling
principle. Cardiovasc Res. 2010;87(2):198–210.
23. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx
model of transvascular fluid exchange: an improved paradigm for
prescribing intravenous fluid therapy. Br J Anaesth. 2012;108(3):384–94.
24. Rahbar E, Baer LA, Cotton BA, Holcomb JB, Wade CE. Plasma colloid osmotic
pressure is an early indicator of injury and hemorrhagic shock. Shock.
2014;41(3):181–7.
25. Cardenas JC, Rahbar E, Pommerening MJ, Baer LA, Matijevic N, Cotton BA,
et al. Measuring thrombin generation as a tool for predicting hemostatic
potential and transfusion requirements following trauma. J Trauma Acute
Care Surg. 2014;77(6):839–45.
26. Keese CR, Bhawe K, Wegener J, Giaever I. Real-time impedance assay to
follow the invasive activities of metastatic cells in culture. Biotechniques.
2002;33(4):842–4, 6, 8–50.
27. Giaever I, Keese CR. Use of electric fields to monitor the dynamical aspect of
cell behavior in tissue culture. IEEE Trans Biomed Eng. 1986;33(2):242–7.
28. Rahbar E, Fox EE, del Junco DJ, Harvin JA, Holcomb JB, Wade CE, et al. Early
resuscitation intensity as a surrogate for bleeding severity and early
mortality in the PROMMTT study. J Trauma Acute Care Surg. 2013;75:1 Suppl 1.29. Rubio-Gayosso I, Platts SH, Duling BR. Reactive oxygen species mediate
modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol
Heart Circ Physiol. 2006;290(6):H2247–56.
30. Zeng Y, Ebong EE, Fu BM, Tarbell JM. The structural stability of the
endothelial glycocalyx after enzymatic removal of glycosaminoglycans. PLoS
One. 2012;7(8):e43168.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
